Jianmin Fang

Co-founder
CEO and CSO

Dr. Fang Jianmin, our Co-Founder, CEO and CSO, has over 20 years of fruitful experience in biopharma R&D and over 40 drug invention patents. Dr. Fang obtained a Ph.D. in biology from Dalhousie University, Canada, and received post-doctoral training in Harvard Medical School. Among his many roles, he is a member of scientific expert committee of the National Scientific and Technological Major Project for “Major Drug Innovation” (“重大新药创制”国家科技重大专项) of China. He is the inventor for our core products including Telitacicept, Disitamab vedotin and RC28, as well as conbercept, which was the first domestically-developed wet AMD biologic drug in China. Having received approvals for wet AMD in 2013 and pathological myopia choroidal neovascularization (pmCNV) in 2017, conbercept has an over 40% market share of anti-VEGF therapeutics in China in 2019. Dr. Fang is one of the few founders in China’s biopharmaceutical industry with successful track record of progressing novel drug from discovery through commercialization.